A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Upadacitinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 24 Jul 2023 According to AbbVie media release, results from this study are planned for publication in a scientific journal. Additional results will be presented at a future medical congress.
- 21 Mar 2023 Primary endpoint (Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12) has been met, as per results presented at the American Academy of Dermatology annual Meeting 2023.
- 21 Mar 2023 Results assessing the efficacy and safety of upadacitinib versus placebo in adults with moderate-to-severe hidradenitis suppurativa, presented at the American Academy of Dermatology annual Meeting 2023.